Dr. Reddy’s Laboratories has introduced 'Nivorz', a biosimilar cancer therapy, into the Indian market. The product is manufactured at the company's Hyderabad facility. Investors are assessing the move within a market valued at ₹3,900 crore, while also tracking regulatory compliance and competitive pricing dynamics.
Dr. Reddy’s Laboratories has officially launched 'Nivorz' in India, marking the company’s entry into the specialized immuno-oncology market. This new product is a biosimilar version of the cancer drug known internationally as Opdivo. The launch follows approval from the Drugs Controller General of India, which has cleared the drug for 12 indications, covering various solid and haematological malignancies.
The product is being manufactured in-house at the company’s biologics facility located in Bachupally, Hyderabad. According to company data, the clinical development program for Nivorz was conducted across a base of 288 patients, including 252 from India and 36 from Russia. This rollout is part of the company's strategy to expand its portfolio in the complex biologics space, aiming to capture a share of the Indian immuno-oncology market, which was estimated to be worth approximately ₹3,900 crore as of 2025.
Market Reaction and Stock Performance
Following the announcement, shares of Dr. Reddy’s Laboratories closed at ₹1,144.40 on September 15, 2026, marking a decline of 1.82% for the day. While the product launch signifies a strategic step toward portfolio diversification, the stock's movement reflects broader investor caution regarding the company’s near-term performance in competitive segments.
Business Risks and Monitorables
For investors, the long-term impact of this launch will depend on its adoption in the medical community and the company's ability to navigate pricing competition in the biosimilar segment. While the move into immuno-oncology represents a new growth vertical, it also brings specific business challenges. The company faces ongoing regulatory scrutiny, as seen with previous observations from the US Food and Drug Administration (USFDA) at its manufacturing facilities. Maintaining stringent quality standards in biosimilar production is a complex task that requires significant operational oversight.
Furthermore, the pharmaceutical sector often faces price erosion as new competitors enter the market with similar products. Investors may monitor how Dr. Reddy’s manages margins in this segment compared to its traditional generic business. The key monitorable for the coming quarters will be the sales uptake of Nivorz and any updates regarding regulatory inspections or approvals that could impact the company’s manufacturing flexibility.